These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22766526)

  • 1. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe.
    Lakatos PL; Lovasz BD; David G; Pandur T; Erdelyi Z; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Golovics PA; Vegh Z; Mandel M; Horvath A; Szathmari M; Kiss LS; Lakatos L
    J Crohns Colitis; 2013 Jun; 7(5):385-91. PubMed ID: 22766526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study.
    Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA
    Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
    Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
    Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
    Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis.
    Kobayashi T; Uda A; Udagawa E; Hibi T
    J Crohns Colitis; 2020 Jun; 14(5):617-623. PubMed ID: 31867632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort.
    Ashworth LA; Billett A; Mitchell P; Nuti F; Siegel C; Bousvaros A
    Inflamm Bowel Dis; 2012 May; 18(5):838-43. PubMed ID: 21887728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
    Lopez A; Mounier M; Bouvier AM; Carrat F; Maynadié M; Beaugerie L; Peyrin-Biroulet L;
    Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1324-9. PubMed ID: 24582568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
    Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease.
    Müller KE; Lakatos PL; Arató A; Kovács JB; Várkonyi Á; Szűcs D; Szakos E; Sólyom E; Kovács M; Polgár M; Nemes É; Guthy I; Tokodi I; Tóth G; Horváth Á; Tárnok A; Csoszánszki N; Balogh M; Vass N; Bódi P; Dezsőfi A; Gárdos L; Micskey E; Papp M; Cseh Á; Szabó D; Vörös P; Veres G;
    J Pediatr Gastroenterol Nutr; 2013 Nov; 57(5):576-82. PubMed ID: 23820399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
    Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
    Beaugerie L; Brousse N; Bouvier AM; Colombel JF; Lémann M; Cosnes J; Hébuterne X; Cortot A; Bouhnik Y; Gendre JP; Simon T; Maynadié M; Hermine O; Faivre J; Carrat F;
    Lancet; 2009 Nov; 374(9701):1617-25. PubMed ID: 19837455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
    Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
    J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory Bowel Disease Patients Are at Increased Risk of Invasive Pneumococcal Disease: A Nationwide Danish Cohort Study 1977-2013.
    Kantsø B; Simonsen J; Hoffmann S; Valentiner-Branth P; Petersen AM; Jess T
    Am J Gastroenterol; 2015 Nov; 110(11):1582-7. PubMed ID: 26346865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
    Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
    J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008.
    Lakatos PL; David G; Pandur T; Erdelyi Z; Mester G; Balogh M; Szipocs I; Molnar C; Komaromi E; Kiss LS; Lakatos L
    J Crohns Colitis; 2011 Feb; 5(1):5-13. PubMed ID: 21272797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.